REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
=== Pharmacodynamics === Trimebutine is a multimodal drug that acts on many receptors in the body. Its main effects are mediated through inhibition of voltage-gated L-type calcium channels, thereby decreasing calcium influx in smooth muscle in the gut. This mechanism explains its ability to slow peristalsis, which in turn helps with diarrhoea management in IBS patients. Antispasmodic effect is mediated through inhibition of inward rectifier potassium channels and calcium-dependend potassium channels. Moreover, trimebutine and its metabolite N-desmethyltrimebutine exert non-selective antagonistic effect on muscarinic acetylcholine receptors, which is believed to potentiate its antispasmodic effects, as do many other drugs in this class. Moreover, trimebutine and N-desmethyltrimebutine act as weak agonists of opioid receptors, specifically μ-, δ-, and κ-opioid receptor subtypes throughout the gut, which was shown in animal-model studies. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract. This mode of action explains trimebutine's ability to mediate gastrointestinal motility in different parts of the gastrointestinal tract, both stimulating and inhibiting spontaneous contractions. In vitro, trimebutine also exhibits antagonistic effects in sodium channels with IC50 equal 8.4 μM and inhibits glutamate release.
==== Miscellaneous euarchontoglires research ==== Zhang & Wang (2026) revise and study the affinities of fossil lagomorphs from China. A study on the anatomy and affinities of Gymnesicolagus gelaberti is published by Čermák et al. (2026). Zhang & Wang (2026) describe new fossil material of Desmatolagus gobiensis from the Oligocene strata from the Ulantatal site (Inner Mongolia, China) and study the phylogenetic relationships of the species, interpreting it as a basal member of Ochotonidae. Kalaitzi & Kostopoulos (2026) study the forelimb and hindlimb morphology of Trischizolagus dumitrescuae, interpreted as indicative of adaptations for controlled, agile leaping, as well as indicative of more developed running abilities compared to typical rabbits but without the extreme specialization seen in hares. Chester et al. (2026) report the discovery of fossil material of Purgatorius from the Denver Formation (Colorado, United States), representing the first record of a Puercan plesiadapiform south of Montana reported to date. Evidence from the study of virtual endocasts of extant and extinct members of Euarchontoglires, indicative of a shared ancestral endocranial shape in early members of the group, indicating that treeshrews are not a good model for the ancestral endocranial shape in Euarchontoglires, and indicating that primates evolved their modern endocranial morphologies faster than other members of Euarchontoglires, is presented by Lang et al. (2026)
Zebrafish Amphipod Hyalella curvispina, the earthworm Eisenia Andrei Tilapia Oreochromis mossambicus Frog Pseudacris regilla and salamander Ambystoma gracile Toad Rhinella arenarum Rainbow trout oncorhynchus mykiss Comparison between the toad Rhinella arenarum and the rainbow trout oncorhynchus mykiss Comparison between fish Mysidopsis bahia and Cyprinodon variegatus
=== Cholesterol clearance === Synthetic platelets are being explored for their potential in cholesterol clearance by facilitating the targeted removal of cholesterol from the bloodstream, offering a novel approach to treating hypercholesterolemia and preventing cardiovascular diseases. Elevated low-density lipoprotein cholesterol (LDL-C) is a key contributor to coronary heart disease, largely regulated by the interaction between LDL receptors (LDLR) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Since PCSK9 reduces LDLR availability, inhibiting it can enhance LDL-C clearance. To explore this, researchers designed platelet-mimicking nanoparticles to deliver siRNA targeting Pcsk9. These nanoparticles effectively lowered Pcsk9 mRNA levels by 66% in cell studies and reduced plasma LDL-C by 28% in animal models, without significantly altering high-density lipoprotein cholesterol (HDL-C) or triglycerides (TGs). This strategy demonstrates the potential of biomimetic nanoparticles for RNA-based therapies aimed at treating high cholesterol.
Sources: en.wikipedia.org
Kyiv came under air attack in the early hours of the morning. Vitali Klitschko, Kyiv's Mayor, said that debris from intercepted missiles struck the city zoo in the Solomianskyi District and the Shevchenkivskyi District, as well as several cars, and wounded three people. According to Kyiv's military administrator, Serhiy Popko, the attack was "exceptional", as it involved "the maximum number of attack missiles in the shortest period of time." Ukraine stated all eighteen missiles were shot down, including six Kh-47M2 Kinzhal missiles. The attacks came from the north, south and east while being launched from air, land and sea, according to Ukrainian military commander Valerii Zaluzhny. However, Russian Defence Minister Sergei Shoigu dismissed the Ukrainian claims, saying that they had launched a lesser amount of missiles. The Russian Ministry of Defence claimed to have destroyed a US-built Patriot surface-to-air missile defense system with a Kinzhal missile. A US official later told CNN that a Patriot system was likely damaged but not destroyed during the attack, and that assessments for potential damage were ongoing. According to a US official the Patriot system could be repaired in Ukraine. Due to modular nature of the system it may just require the replacement of a damaged component with a new one. Denis Pushilin, head of the Russian-backed Donetsk People's Republic, said that Russian forces had seized several Ukrainian positions near Avdiivka.
== Adverse effects == A serious side-effect of heparin is heparin-induced thrombocytopenia (HIT), caused by an immunological reaction that makes platelets a target of immunological response, resulting in the degradation of platelets, which causes thrombocytopenia. This condition is usually reversed on discontinuation, and in general can be avoided with the use of synthetic heparins. Not all patients with heparin antibodies will develop thrombocytopenia. Also, a benign form of thrombocytopenia is associated with early heparin use, which resolves without stopping heparin. Approximately one-third of patients with diagnosed heparin-induced thrombocytopenia will ultimately develop thrombotic complications. Two non-hemorrhagic side effects of heparin treatment are known. The first is an elevation of serum aminotransferase levels, which has been reported in as many as 80% of patients receiving heparin. This abnormality is not associated with liver dysfunction, and it disappears after the drug is discontinued. The other complication is hyperkalemia, which occurs in 5 to 10% of patients receiving heparin, and is the result of heparin-induced aldosterone suppression. The hyperkalemia can appear within a few days after the onset of heparin therapy. More rarely, the side-effects alopecia and osteoporosis can occur with chronic use. As with many drugs, overdoses of heparin can be fatal. In September 2006, heparin received worldwide publicity when three prematurely born infants died after they were mistakenly given overdoses of heparin at an Indianapolis hospital.
Bezitramide is an opioid analgesic. Bezitramide itself is a prodrug which is readily hydrolyzed in the gastrointestinal tract to its active metabolite, despropionyl-bezitramide. Bezitramide was discovered at Janssen Pharmaceutica in 1961. It is most commonly marketed under the trade name Burgodin. The drug was pulled from the shelves in the Netherlands in 2004 after fatal overdose cases, including one where a five-year-old child took one tablet from his mother's purse, ate it, and promptly died. Bezitramide is regulated much the same as morphine in all known jurisdictions and is a Schedule II substance under the United States' Controlled Substances Act of 1970, with an ACSCN of 9800 and zero annual manufacturing quota. However, as of May 2021, it has never been marketed in the United States.
Induces endometrial secretory transformation in preparation for pregnancy (>5 ng/mL) Prevents estrogen-induced endometrial hyperplasia and increased endometrial cancer risk Maintains pregnancy via effects in endometrium (with withdrawal resulting in miscarriage) Reduces amount and fibrosity of cervical mucus and causes cervix to become firmer and more tightly closed Controls motility and composition of fluid in the fallopian tubes Reduced cornification and maturation of the vaginal lining Causes water retention in the breasts resulting in temporary enlargement during the menstrual cycle Mediates lobuloalveolar development of the breasts necessary for lactation Suppresses lactation initiation and triggers lactation upon withdrawal (as with parturition) Maintains skin health, integrity, appearance, and hydration and slows the rate of aging of the skin Modulates brain function, with effects on mood, emotionality, and sexuality, as well as cognition and memory Exerts negative feedback on the hypothalamic–pituitary–gonadal axis (HPG axis) by suppressing the secretion of the gonadotropins FSH and LH from the pituitary gland (including the mid-cycle gonadotropin surge), thereby inhibiting gonadal sex hormone production as well as ovulation and fertility (>2 ng/mL) Increases basal body temperature (by 0.3–0.6 °C (0.5–1.0 °F) relative to preovulation) via the hypothalamus (>4 ng/mL) Reduces hot flashes via the hypothalamus Stimulates respiration via the hypothalamus and/or respiratory center Influences the risk and/or progression of hormone-sensitive cancers including breast cancer and endometrial cancer Many of the effects of progesterone require estrogen, as estrogens prime tissues for progesterone by inducing expression of the PRs. The PRs are induced in the breasts by estrogens, and for this reason, it is assumed that progestogens cannot mediate breast changes in the absence of estrogens. Progesterone also lowers blood pressure and reduces water and salt retention among other effects via its antimineralocorticoid activity. Progesterone can produce sedative, hypnotic, anxiolytic, euphoric, cognitive-, memory-, and motor-impairing, anticonvulsant, and even anesthetic effects via formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABAA receptor potentiation in the brain.
Jens Juul Holst (born 31 August 1945) is a Danish physician and physiologist. He is known for discovering and describing the hormone glucagon-like peptide-1 (GLP-1), a hormone in the gut that plays an important role in the onset and development of Type 2 diabetes. In collaboration with researcher and author Arne Astrup, he discovered that GLP-1 acts as a satiety hormone in humans. In 2020, he was awarded the Warren Alpert Foundation Prize along Daniel J. Drucker and Joel F. Habener. In 2021, he was awarded the Canada Gairdner International Award along Daniel J. Drucker, Joel F. Habener, and Mary-Claire King. He was also awarded the Banting Medal by the American Diabetes Association (ADA). In 2024, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, and Svetlana Mojsov. In 2024, he received the Tang Prize in the category of "Biopharmaceutical Science", and the BBVA Foundation Frontiers of Knowledge Award in the category "Biology and Biomedicine". In 2025, he received the Breakthrough Prize in Life Sciences alongside Daniel Drucker, Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen).
Sources: en.wikipedia.org
=== Pore size === Many stationary phases are porous to provide greater surface area. Small pores provide greater surface area while larger pore size has better kinetics, especially for larger analytes. For example, a protein which is only slightly smaller than a pore might enter the pore but does not easily leave once inside.
== Research == AAS, alone and in combination with progestogens, have been studied as potential male hormonal contraceptives. Dual AAS and progestins such as trestolone and dimethandrolone undecanoate have also been studied as male contraceptives, with the latter under active investigation as of 2018. Topical androgens have been used and studied in the treatment of cellulite in women. Topical androstanolone on the abdomen has been found to significantly decrease subcutaneous abdominal fat in women, and hence may be useful for improving body silhouette. However, men and hyperandrogenic women have higher amounts of abdominal fat than healthy women, and androgens have been found to increase abdominal fat in postmenopausal women and transgender men as well.
=== Physical === Organic molecular cages exhibit permanent porosity in both solution and solid state. Typical surface areas range from 500 to 3000 m²/g, with pore volumes varying based on cage geometry. Most organic cages demonstrate high thermal stability up to 300 °C. Solubility represents another key physical property, with most cages showing good solubility in common organic solvents. This solution processability enables their incorporation into membranes and composite materials. The mechanical properties of cage crystals depend on packing arrangements and intermolecular interactions. While individual cage molecules are robust due to their covalent nature, crystal mechanical properties can range from brittle to flexible depending on intermolecular forces. Shape persistence varies with cage structure, affecting their stability and guest binding properties.
=== MSIR model === For many infections, including measles, babies are not born into the susceptible compartment but are immune to the disease for the first few months of life due to protection from maternal antibodies (passed across the placenta and additionally through colostrum). This is called passive immunity. This added detail can be shown by including an M class (for maternally derived immunity) at the beginning of the model.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.